IL-12 and IL-23 pathway inhibition in inflammatory bowel disease

被引：0

作者：

Bram Verstockt

Azucena Salas

Bruce E. Sands

Clara Abraham

Haim Leibovitzh

Markus F. Neurath

Niels Vande Casteele

机构：

[1] University Hospitals Leuven,KU Leuven Department of Chronic Diseases and Metabolism

[2] Department of Gastroenterology and Hepatology,Inflammatory Bowel Disease Unit, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

[3] KU Leuven,Dr. Henry D. Janowitz Division of Gastroenterology

[4] Translational Research Center for Gastrointestinal Disorders (TARGID),Department of Medicine

[5] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD),Zane Cohen Centre for Digestive Diseases, Division of Gastroenterology & Hepatology, Temerty Faculty of Medicine, Mount Sinai Hospital

[6] Icahn School of Medicine at Mount Sinai,Department of Medicine 1

[7] Yale University,Deutsches Zentrum Immuntherapie DZI

[8] University of Toronto,Department of Medicine

[9] University Erlangen-Nürnberg,Gastroenterology and Endoscopy

[10] University Erlangen-Nürnberg,Amsterdam UMC, Amsterdam Medical Center

[11] University of California San Diego,Metabolism Research Institute, Amsterdam UMC

[12] IRCCS Ospedale San Raffaele,Division of Gastroenterology

[13] University Vita-Salute San Raffaele,Division of Gastroenterology and Hepatology

[14] University of Amsterdam,Departments of Medicine and Epidemiology and Biostatistics

[15] Department of Gastroenterology and Hepatology,Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences

[16] University of Amsterdam,Precision Institute of Immunology

[17] University of California San Diego,Department of Gastroenterology, Hepatology and Nutrition

[18] Mayo Clinic,Department of Inflammation and Immunity, Lerner Research Institute

[19] Western University,Mount Sinai Hospital IBD Centre

[20] University of Calgary,Department of Biomedical Sciences

[21] Icahn School of Medicine at Mount Sinai,Laboratory of Gastrointestinal Immunopathology

[22] Digestive Diseases and Surgery Institute,undefined

[23] Cleveland Clinic Foundation,undefined

[24] Cleveland Clinic Foundation,undefined

[25] University of Toronto,undefined

[26] Humanitas University,undefined

[27] Pieve Emanuele,undefined

[28] IRCCS Humanitas Research Hospital — IRCCS,undefined

[29] Rozzano,undefined

来源：

Nature Reviews Gastroenterology & Hepatology | 2023年 / 20卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Interleukin-12 (IL-12) and interleukin-23 (IL-23), which belong to the IL-12 family of cytokines, have a key role in intestinal homeostasis and inflammation and are implicated in the pathogenesis of inflammatory bowel disease. Upon their secretion by antigen-presenting cells, they exert both pro-inflammatory and anti-inflammatory receptor-mediated effects. An increased understanding of these biological effects, particularly the pro-inflammatory effects mediated by IL-12 and IL-23, has led to the development of monoclonal antibodies that target a subunit common to IL-12 and IL-23 (p40; targeted by ustekinumab and briakinumab), or the IL-23-specific subunit (p19; targeted by risankizumab, guselkumab, brazikumab and mirikizumab). This Review provides a summary of the biology of the IL-12 family cytokines IL-12 and IL-23, discusses the role of these cytokines in intestinal homeostasis and inflammation, and highlights IL-12- and IL-23-directed drug development for the treatment of Crohn’s disease and ulcerative colitis.

引用

页码：433 / 446

页数：13

共 50 条

[1] IL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Verstockt, Bram
Salas, Azucena
Sands, Bruce E.
Abraham, Clara
Leibovitzh, Haim
Neurath, Markus
Vande Casteele, Niels
[J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (07) : 433 - 446
[2] Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Ahmed Almradi
Jurij Hanzel
Rocio Sedano
Claire E. Parker
Brian G. Feagan
Christopher Ma
Vipul Jairath
[J]. BioDrugs, 2020, 34 : 713 - 721
[3] Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease
Almradi, Ahmed
Hanzel, Jurij
Sedano, Rocio
Parker, Claire E.
Feagan, Brian G.
Ma, Christopher
Jairath, Vipul
[J]. BIODRUGS, 2020, 34 (06) : 713 - 721
[4] IL-12/IL-23 pathway inhibition has therapeutic potential in Alzheimer disease
[J]. Nature Reviews Neurology, 2013, 9 (2) : 61 - 61
[5] IL-12 and IL-23 in health and disease
Stetsko, Dawn
Sauder, Daniel N.
[J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2008, 4 (03) : 301 - 303
[6] The IL-23/IL-17 pathway in inflammatory bowel disease
Geremia, Alessandra
Jewell, Derek P.
[J]. EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2012, 6 (02) : 223 - 237
[7] Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency
Mannon, Peter J.
Fuss, Ivan J.
Dill, Susie
Friend, Julia
Groden, Catherine
Hornung, Ron
Yang, Zhiqiong
Yi, Chuli
Quezado, Martha
Brown, Margaret
Strober, Warren
[J]. GASTROENTEROLOGY, 2006, 131 (03) : 748 - 756
[8] Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases
Danesi, Francesca
Philpott, Martin
Huebner, Claudia
Bordoni, Alessandra
Ferguson, Lynnette R.
[J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2010, 690 (1-2) : 139 - 144
[9] Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
Cayatte, Corinne
Joyce-Shaikh, Barbara
Vega, Felix
Boniface, Katia
Grein, Jeffrey
Murphy, Erin
Blumenschein, Wendy M.
Chen, Smiley
Malinao, Maria-Christina
Basham, Beth
Pierce, Robert H.
Bowman, Edward P.
McKenzie, Brent S.
Elson, Charles O.
Faubion, William A.
Malefyt, Rene de Waal
Kastelein, Robert A.
Cua, Daniel
McClanahan, Terrill K.
Beaumont, Maribel
[J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2012, 3
[10] IL-12/IL-23 inhibitors: a promising approach to the treatment of inflammatory disorders
Wada, Yumiko
[J]. DRUGS OF THE FUTURE, 2008, 33 (01) : 49 - 63

← 1 2 3 4 5 →